| Rigel Pharmaceuticals is a biotechnology company focused on discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Co.'s U.S. Food and Drug Administration approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, an oral spleen tyrosine kinase inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe, the U.K. (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients. We show 52 historical shares outstanding datapoints in our RIGL shares outstanding history coverage, used to compute RIGL market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing RIGL market cap history over the course of time is important for investors
interested in comparing RIGL's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of RIGL versus a peer is one thing; comparing
RIGL market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like RIGL can fluctuate over the course of history.
With this page we aim to empower investors researching RIGL by allowing them to research the RIGL market cap history.